ProMIS, Selexis to Develop Antibody Targeting Toxic Amyloid Beta

ProMIS, Selexis to Develop Antibody Targeting Toxic Amyloid Beta

295206

ProMIS, Selexis to Develop Antibody Targeting Toxic Amyloid Beta

ProMIS Neurosciences will advance the development of PMN310, its manmade antibody designed to target the toxic forms of amyloid beta that underlie Alzheimer’s disease. The first step in the manufacturing of PMN310 will be carried out by Selexis with its proprietary CHO-K1 cell line, part of the company’s SUREtechnology platform. The platform uses Selexis’ optimized, high-performance mammalian (Chinese hamster ovary) cell line which allows for faster and more efficient scale-up production of the antibody of choice. Vehicles, called…

You must be logged in to read/download the full post.